Intracellular processing of 99Tcm-antibody conjugates

Area of Science:

• Nuclear Medicine
• Oncology
• Immunology

Background:

• Investigating the intracellular fate of radiolabeled antibodies is crucial for targeted cancer therapy.
• Antibody LL1, targeting the MHC class II invariant chain, is rapidly internalized by B-cell lymphomas.
• Understanding radiolabel catabolism informs the design of effective diagnostic and therapeutic agents.

Purpose of the Study:

• To investigate the catabolism and intracellular retention of Technetium-99m (99Tcm)-labeled antibody LL1 conjugates in B-cell lymphomas.
• To compare the retention characteristics of 99Tcm with other radiolabels like Indium-111 diethylenetriamine pentaacetate (111In-DTPA) and iodine.

Main Methods:

• Antibody LL1 was labeled with 99Tcm following mild reduction.
• Internalization and intracellular retention of the 99Tcm-antibody conjugate were studied in B-cell lymphoma models.
• Comparison of 99Tcm retention with 111In-DTPA and conventional iodine labels.

Main Results:

• The 99Tcm label demonstrated strong intracellular retention, comparable to residualizing labels like 111In-DTPA.
• Unlike 111In-DTPA, 99Tcm was not found in a low molecular weight form but bound to various cellular proteins.
• 99Tcm was retained in the cytoplasm, not lysosomes, indicating a novel intracellular retention mechanism.

Conclusions:

• 99Tcm-antibody conjugates exhibit a unique intracellular retention mechanism, binding to cellular proteins in the cytoplasm.
• This behavior differs from conventional labels and represents a new paradigm for radiolabel intracellular retention.
• The findings support the potential of 99Tcm-labeled antibodies for targeted B-cell lymphoma therapies.